Discover and read the best of Twitter Threads about #DCLUNG19
Most recents (2)
#DCLUNG19 Daunting task of all non-EGFR/ALK drivers in #NSCLC handled easily by @alexdrilon - in #ROS1, note that not all ALK inhibitors are ROS1 inhibitors. Variation in CNS activity. Many active drugs to consider. #LCSM #LCAM 
#DCLUNG19 Highly active, CNS penetrant and well tolerated TKIs for #RET and #NTRK fusion positive cancers, outlined by expert @alexdrilon
#DCLUNG19 Impressive discussion of #ALK targeted therapy and resistance by global expert @JessicaJLinMD - great 1L options with a wonderful summary table. #LCSM #LCAM
#DCLUNG19 Resistance in #ALK dictated by initial therapy. Clinical findings replicate preclinical models: I1171N seen post alectinib but not brigatinib or ceritinib. G1202R an issue for all. Clinical data coming in now. #OncoAlert #LCSM #LCAM
#DCLUNG19 Lorlatinib is a very active drug in refractory #ALK #NSCLC with good CNS penetration but efficacy greater if solvent front mutation detected. Still with responses in absence of mutation. Chemo still an option as well. Next challenge: compound mutations! #OncoAlert
